Baba Ramdev’s Patanjali on track to hit $1 Billion Sales in FY17
Baba Ramdev’s Patanjali on track to hit $1 Billion Sales – Which means, Patanjali could become the fifth largest FMCG company in the country, after Hindustan Unilever, ITC, Nestle India and Britannia Industries.
At Patanjali Ayurved’s manufacturing facility in Haridwar, there is brisk activity as cartons of freshly made products are being loaded onto trucks to be dispatched to stores across India. With the financial year nearing a close, an official pointed explained, all hands are on the deck to help the company achieve its targeted turnover of Rs 5,000 crore this fiscal.
For a manufacturing company set up about 10 years ago, achieving a Rs 5,000-crore turnover is not easy . However, for Patanjali Ayurved, which is breaking conventional marketing norms, sales are inching up month on month. Sources in the know believe Patanjali could have clocked monthly sales of around Rs 600-700 crore in January and February, which means Baba Ramdev’s baby could become a billiondollar entity, with its annualized turnover expected to cross the Rs 7,000-crore mark before the end of fiscal 2017.
Which means, Patanjali could become the fifth largest FMCG company in the country, after Hindustan Unilever, ITC, Nestle India and Britannia Industries. This would bring it well ahead of traditional FMCG players like Dabur, Godrej Consumer Products and Marico.
“We may even reach Rs 600 crore a month mark -that will give us an annual turnover of approximately Rs 7,000 crore,” said Balkrishna.
Even at the current level of Rs 4,500-crore turnover, Patanjali has paced ahead of oral care leader Colgate-Palmolive (India), challenging it which its `Dant Kanti’ toothpaste.
The Indian government has banned the so called ‘English medicine’, around 344 fixed dosed combination drugs, including Pfizer’s cough syrup Corex, Procter & Gamble’s Vicks Action 500 Extra and Crocin Cold and Flu, this week citing their potential risks.
“As per estimate, each FDC has at least 5 to 10 brands in the market, which means around 1,200 more drugs are likely to be banned,” the official at CDSCO added.
Given that Patanjali has been grabbing eyeballs through its advertising, industry experts believe the company could soon even reach Rs 10,000 crore turnover.